AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
FDA Follows Advisory Panel Recommendation On PARP Inhibitor
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.